Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Heron Therapeutics Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 185× Heron Therapeutics Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Heron Therapeutics Inc for 35 Days on average.
| HALO | HRTX | |
|---|---|---|
Market Cap | $12.58B | $68.01M |
Volume | 2,179,278 | 1,891,941 |
Sector | Health | Health |
52-Week High | $115.22 | $1.49 |
52-Week Low | $61.63 | $0.27 |
Typical Hold Time | 1 Days | 35 Days |
Enterprise Value | $14.49B | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
